Dr. Breggin’s work has helped to change the contents of numerous FDA-approved labels for psychiatric drugs, including the neuroleptic (antipsychotic) drugs and the newer antidepressants. This section makes available some of Dr. Breggin’s articles about recent label changes for the antidepressants, as well his critiques and presentations to the FDA.
Dr. Breggin’s commentaries in this section surround the FDA’s actions in adding suicidality in children and young adults to the labels for antidepressants. The language in the new FDA-mandated labels closely adheres to concepts first published in Dr. Breggin’s earlier books and articles concerning suicide, violence, and over-stimulation caused by SSRIs. As described in the first commentary, the FDA’s language seems to mimic his wording.
For the science behind these commentaries, see Dr. Breggin’s book, Brain-Disabling Treatments in Psychiatry, Second Edition, as well as his scientific articles. In several of his books, Dr. Breggin devotes chapters to the inadequacy of the FDA, most recently Brain-Disabling Treatments in Psychiatry, Second Edition and Medication Madness. One of the most detailed analyses ever published of the FDA’s bungling and a drug company’s manipulation of the drug approval process can be found in Talking Back to Prozac (with Ginger Breggin, 2004).
Dr. Breggin’s published articles on SSRI antidepressants, including medication-induced violence, suicide and crime, often discuss the FDA. His article “Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRIs): A review and analysis” was given to the FDA’s committee prior to their deliberations.
The following section contains articles and commentaries by Dr. Breggin concerning the FDA, especially in regard to the newer antidepressants.

Recent regulatory changes in antidepressant labels: Implications for activation (stimulation)
Jun 09, 2008 | the-fda-articles-critiques-and-presentations
recentregulatory.pbreggin.2006.pdf
Read More
Recent U.S., Canadian and British regulatory agency actions concerning antidepressant-induced harm (2004)
Jun 09, 2008 | the-fda-articles-critiques-and-presentations
recentus.pbreggin.2004.pdf
Read More
Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRIs): A review and analysis (2004)
Sep 06, 2004 | ssris-and-other-antidepressants frequently-read-articles selected-scientific-papers the-fda-articles-critiques-and-presentations scientific-papers
Breggin, P.R. International Journal of Risk and Sa...
Read More
Antidepressant-induced suicidality and violence: more about deception than science (2004)
Jan 15, 2004 | ssris-and-other-antidepressants the-fda-articles-critiques-and-presentations
Report presented at the September 14, 2004 press c...
Read More
Violence and suicide caused by antidepressants: report to the FDA (2004)
Jan 15, 2004 | ssris-and-other-antidepressants the-fda-articles-critiques-and-presentations
A report Dr. Breggin presented to the FDA in Augus...
Read More
Proven Dangers of Antidepressants (2004)
Jan 12, 2004 | ssris-and-other-antidepressants the-fda-articles-critiques-and-presentations
Dangers of antidepressants. Newspaper column--s...
Read More
Speech to FDA Panel, 2 Feb 2004
Jan 12, 2004 | ssris-and-other-antidepressants the-fda-articles-critiques-and-presentations
SSRIs produce a continuum of stimulation that incl...
Read More
Court filing makes public my previously suppressed analysis of Paxil's effects
Jan 14, 2003 | the-fda-articles-critiques-and-presentations
Information on antidepressant-induced akathisia c...
Read More
Fluvoxamine as a cause of stimulation, mania and aggression with a critical analysis of the FDA-approved label (2001)
Jan 15, 2001 | ssri-articles ssris-and-other-antidepressants the-fda-articles-critiques-and-presentations scientific-papers
Breggin, PR. (2001) International Journal of Risk ...
Read More
Drug Company Suppressed Data on Paroxetine-Induced Stimulation
Jan 12, 2001 | the-fda-articles-critiques-and-presentations
Paxil Special Report III: The third special repor...
Read More